Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by Staghorn69on Jul 25, 2017 12:19pm
184 Views
Post# 26506354

RE:Reading the PG deficiency FB page---posters are as

RE:Reading the PG deficiency FB page---posters are as"Miracle drug"....  makes me wonder if the FB page posters are as reputable as many of the paid pumpers that used to and still rave on this board...  the "miracle drug" that can't get a deal and can't even get a response from FDA.  Given our track record, and until I hear otherwise, I'll presume that Prometic deficiencies in the BLA are responsible for the delay....  blaming A regulatory body for the delay in this phase is just too easy.  
Bullboard Posts